A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants
Status:
COMPLETED
Trial end date:
2025-06-17
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time, called a pharmacokinetic (PK) study. Researchers want to learn if there is a difference in the healthy person's body when MK-8527 is taken as a single dose (Treatment A) or with the medication Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Treatment B).
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination